The 27th annual meeting of the Spanish Lymphoma and Autologous Bone Marrow Transplant Group (Geltamo), a working group of the Spanish Society of Hematology and Hemotherapy (SEHH), brought together nearly 200 specialists from all over Spain at the Alfredo Kraus auditorium in Las Palmas de Gran Canaria. The meeting focused on the main advances in the diagnosis and treatment of lymphomas, with a particular emphasis on advanced therapies.

Each year, more than 9,000 new cases of non-Hodgkin lymphoma are diagnosed in Spain. Thanks to therapeutic progress, five-year survival now exceeds 75% in many subtypes, a fact that underscores the importance of these advancements.

CAR-T therapies are enabling up to 50% of patients with no other options to achieve prolonged remissions and, potentially, lymphoma cure, marking a milestone in the treatment of these diseases. The scientific program of the meeting addressed the current and future challenges of these cellular therapies.

A hematologist from Hospital Vall d'Hebron in Barcelona analyzed real-world experience and the development of dual CAR-T, highlighting the need for faster and more efficient manufacturing, preservation of lymphocyte quality, and the development of targeted therapies for new targets. She also emphasized the importance of multidisciplinary work and expanding equitable access to these treatments across all autonomous communities.

In the Canary Islands, significant progress has been made in accessing innovative therapies for lymphoma patients, thanks to coordination between centers and the consolidation of specialized units. The Hospital Universitario de Gran Canaria Doctor Negrín has become a benchmark in the multidisciplinary management of these patients and the progressive incorporation of advanced treatments, improving both survival and quality of life.